Causse X, Payen J L, Izopet J, Babany G, Girardin M F
Hepatogastroenterology Unit, CHR Orléans La Source, France.
J Hepatol. 2000 Jun;32(6):1003-10. doi: 10.1016/s0168-8278(00)80105-1.
BACKGROUND/AIM: The aim of this prospective study was to compare the response to alfa-interferon treatment of chronic hepatitis C in two groups of patients: coinfected with human immunodeficiency virus (HIV) (G I) or not (G II).
One hundred and fifty-three patients with chronic hepatitis C had been enrolled in 30 French liver units or infectious diseases units between May 1992 and January 1995 (G I: 76, G II: 77) to receive alfa-2a interferon: 3 MU thrice weekly for 6 months.
One hundred and twenty-seven patients (G I: 63, G II: 64) fulfilled all criteria for analysis. The two groups were comparable for all demographic data, while significantly more severe biological and histological (p=0.001) parameters attested to more serious hepatitis among HIV-HCV coinfected patients. HCV viremia was higher among HIV-coinfected patients (p=0.0169), while genotype repartition was identical among the two groups (more than 52% of genotype 1, more than 31% of genotype 3). ALT normalization was, respectively, (G I/G II) obtained in 17.46%/26.56% (not significant) of patients at the end of treatment and in 11.11%/12.5% (not significant) of patients after 6 months of follow-up. In a multivariate analysis, GGT level before therapy (relative risk 2.1, confidence interval 1.1-5.8) and body surface area (relative risk 1.9, confidence interval 1.1-3.7) were the variables independently associated with the response to alfa-interferon treatment (higher GGT and more elevated body surface area were associated with a risk of non-response).
In our study HIV infection did not affect the alfa-interferon treatment response of chronic hepatitis C, and response could be achieved among HIV-coinfected patients. Present therapeutic anti-HCV schedules need to be proposed to HIV-HCV coinfected patients before severe immunosuppression occurs. On the other hand, more severe biological and histological parameters were observed among HIV-HCV coinfected patients, which suggests a need to study whether HIV infection is associated with a worsening course of chronic hepatitis C.
背景/目的:本前瞻性研究旨在比较两组慢性丙型肝炎患者对α干扰素治疗的反应:合并人类免疫缺陷病毒(HIV)感染的患者(第一组)和未合并HIV感染的患者(第二组)。
1992年5月至1995年1月期间,153例慢性丙型肝炎患者被纳入法国30个肝病科或传染病科(第一组76例,第二组77例),接受α-2a干扰素治疗:每周三次,每次3MU,共6个月。
127例患者(第一组63例,第二组64例)符合所有分析标准。两组在所有人口统计学数据方面具有可比性,而合并HIV-HCV感染的患者中,更严重的生物学和组织学(p=0.001)参数表明肝炎更为严重。合并HIV感染的患者中HCV病毒血症更高(p=0.0169),而两组的基因型分布相同(基因型1超过52%,基因型3超过31%)。治疗结束时,分别有17.46%/26.56%(无显著差异)的患者(第一组/第二组)实现ALT正常化,随访6个月后,分别有11.11%/12.5%(无显著差异)的患者实现ALT正常化。在多变量分析中,治疗前的GGT水平(相对风险2.1,置信区间1.1-5.8)和体表面积(相对风险1.9,置信区间1.1-3.7)是与α干扰素治疗反应独立相关的变量(较高的GGT和较大的体表面积与无反应风险相关)。
在我们的研究中,HIV感染不影响慢性丙型肝炎的α干扰素治疗反应,合并HIV感染的患者也可实现反应。需要在严重免疫抑制发生前,为合并HIV-HCV感染的患者制定当前的抗HCV治疗方案。另一方面,在合并HIV-HCV感染的患者中观察到更严重的生物学和组织学参数,这表明需要研究HIV感染是否与慢性丙型肝炎病程恶化有关。